Stabilization of insulin through ligand binding interations

• US 5,830,999 A
• Filed: 01/26/1995
• Issued: 11/03/1998
• Est. Priority Date: 01/26/1995
• Status: Expired due to Fees

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Dunn, Michael F.
• Primary Examiner(s): Hill, Jr., Robert J.
• Assistant Examiner(s): HARLE, JENNIFER I
• Application Number:
  US08/378,412
• Time in Patent Office: 1,377 Days
• Field of Search: 514/2, 514/3, 514/4, 530/303, 530/304, 530/305
• US Class Current: 530/303
• CPC Class Codes: A61K 2039/541 Mucosal route
• CPC Class Codes: A61K 2039/55511 Organic adjuvants
• CPC Class Codes: A61K 2039/55583 Polysaccharides
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 39/02 Bacterial antigens
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants

Abstract

Insulin formulations containing ligands for the insulin hexamer which bind several orders of magnitude more tightly to the hexamer than chlorine ion or acetate ion. These ligands are aliphatic and aromatic carboxylates having a dissociation constant (K_D) of less than about 5 mM, and preferably less than about 1 mM. The increased tightness of binding conveys additional stability to the insulin hexamers, improving their usefulness in slow release and fast acting formulations (for example, for the treatment of diabetics).

Claims

1. A composition comprising insulin hexamers, said hexamers having a T₃ R₃ or R₆ conformation, said conformation stabilized by at least one ligand having a dissociation constant K_D of less than about 5 mM, said ligand being selected from the group consisting of aliphatic carboxylic acids or their salts comprising aliphatic acids of at least 5 to 12 carbon atoms and aromatic carboxylic acids or their salts, wherein the aromatic carboxylic acids or their salts comprise at least one aromatic ring selected from the group consisting of phenyl, naphthyl, pyrrolyl imidazolyl, indolyl and 4-oxo-1.4-pyranyl and wherein the aliphatic carboxylic acids or aromatic carboxylic acids can be substituted with hydroxylate anion, thiolate anion, hydroxy, methoxy, amino, alkyl, nitro, or amido groups.

2. A composition according to claim 1, wherein the ligand has a dissociation constant K_D of less than about 1 mM.

3. A composition according to claim 1, wherein the ligand incorporates a three-fold symmetry element.

4. A composition according to claim 3, wherein the ligand is selected from the group consisting of trialkylacetates and adamantane-1-carboxylate.

5. A composition according to claim 1, wherein the ligand is selected from the group of aliphatic carboxylic acids or their salts comprising at least 8 carbon atoms.

6. A composition according to claim 1, wherein the ligand is an aromatic carboxylic acid or its salt selected from the group consisting of 3-nitro4-hydroxybenzoic acid, 4-amino-3-hydroxybenzoic acid, m-nitrobenzoic acid, p-hydroxybenzoic acid, p-aminobenzoic acid, p-acetamidobenzoic acid, benzoic acid, 3-amino4-hydroxybenzoic acid, 3-hydroxy-4-nitrobenzoic acid, 3,5-dinitrobenzoic acid, 3-indoleacrylic acid, p-dimethylaminocinnamic acid, indole-3-carboxylic acid, 4-hydroxycinnamic acid, 3-nitrocinnamic acid, 2-napthylacetic acid, isophthalic acid, 2-methyl-3-nitrobenzoic acid, urocanic acid, p-hydoxyphenylacetic acid and coumalic acid.